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REVIEW
Accounting for equity considerations 
in cost-efectiveness analysis: a systematic 
review of rotavirus vaccine in low- 
and middle-income countries
Marie-Anne Boujaoude1, Andrew J. Mirelman2, Kim Dalziel3 and Natalie Carvalho4* 
Abstract 
Background: Cost-effectiveness analysis (CEA) is frequently used as an input for guiding priority setting in health. 
However, CEA seldom incorporates information about trade-offs between total health gains and equity impacts of 
interventions. This study investigates to what extent equity considerations have been taken into account in CEA in 
low- and middle-income countries (LMICs), using rotavirus vaccination as a case study.
Methods: Specific equity-related indicators for vaccination were first mapped to the Guidance on Priority Setting in 
Health Care (GPS-Health) checklist criteria. Economic evaluations of rotavirus vaccine in LMICs identified via a sys-
tematic review of the literature were assessed to explore the extent to which equity was considered in the research 
objectives and analysis, and whether it was reflected in the evaluation results.
Results: The mapping process resulted in 18 unique indicators. Under the ‘disease and intervention’ criteria, severity 
of illness was incorporated in 75% of the articles, age distribution of the disease in 70%, and presence of comorbidi-
ties in 5%. For the ‘social groups’ criteria, relative coverage reflecting wealth-based coverage inequality was taken into 
account in 30% of the articles, geographic location in 27%, household income level in 8%, and sex at birth in 5%. For 
the criteria of ‘protection against the financial and social effects of ill health’, age weighting was incorporated in 43% 
of the articles, societal perspective in 58%, caregiver’s loss of productivity in 45%, and financial risk protection in 5%. 
Overall, some articles incorporated the indicators in their model inputs (20%) while the majority (80%) presented 
results (costs, health outcomes, or incremental cost-effectiveness ratios) differentiated according to the indicators. 
Critically, less than a fifth (17%) of articles incorporating indicators did so due to an explicit study objective related to 
capturing equity considerations. Most indicators were increasingly incorporated over time, with a notable exception 
of age-weighting of DALYs.
Conclusion: Integrating equity criteria in CEA can help policy-makers better understand the distributional impact 
of health interventions. This study illustrates how equity considerations are currently being incorporated within CEA 
of rotavirus vaccination and highlights the components of equity that have been used in studies in LMICs. Areas for 
further improvement are identified.
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Background
Equity constitutes an integral aim of public health poli-
cies worldwide. he importance of addressing health 
inequities as a goal in the health sector in both devel-
oping and developed countries was explicitly stated in 
the Declaration of Alma-Ata in 1978 [1]. his focus has 
translated into the academic arena, with 216% more 
articles published in MEDLINE having the word equity 
in their abstracts in 2015 compared to those published 
in 1980 [2]. From a policy perspective, equity is at the 
heart of the United Nations’ 2030 Agenda for Sustainable 
Development, with several task forces and committees 
established to work towards equity goals.
Whether referred to as fairness or social justice, health 
equity alludes to the fair distribution health. It concerns 
the diferences in population health that can be traced 
to unequal economic or social conditions [3]. Accord-
ing to Culyer’s interpretation of Aristotle, equity can be 
distinguished as horizontal and vertical equity: horizon-
tal equity entitles like treatment for like individuals and 
vertical equity unlike treatment for unlike individuals in 
proportion to the diferences between them [4]. A range 
of methods have been proposed to quantify the magni-
tude of health inequity, including rate ratios, population 
attributable risks, slope and relative indices of inequality, 
and the concentration curve and index [5].
Given the limited resources available to fund health 
systems, cost efectiveness analysis (CEA) is a useful tool 
to guide the allocation of health budgets. Decision mak-
ers are simultaneously seeking to achieve diverse goals 
such as: maximizing health, reducing health inequities 
and providing protection against the costs of ill health 
[6]. CEA results provide evidence on how to maximize 
health beneits within a given budget, accounting for the 
societal value of health. CEA, however, does not gener-
ally provide information about the distributional value of 
health beneits in a given setting [7]. In fact the CHEERS 
guideline does not mention equity as an item to include 
when reporting economic evaluations of health interven-
tions [8]. Despite this limitation, many guidelines suggest 
that social value judgments can be implicitly incorpo-
rated in CEA by choosing which parameters to include in 
the analysis [9] or by adhering to certain principles such 
as those in the Gates Reference Case [10]. he Guidance 
on Priority Setting in Health Care (GPS-Health) devel-
oped by Norheim et  al. in 2014 constitutes an explicit 
guidance on the inclusion of fairness in the decision-
making process. It lays out a set of criteria to go beyond 
health maximization as relected by traditional cost-
efectiveness alone by providing a list of the equity-rele-
vant dimensions that can be explicitly integrated in CEA.
Previous systematic reviews, studies and guides have 
proposed many approaches to integrate equity concerns 
into CEA. Earlier reviews, mainly Sassi et  al. [11] and 
Hauck et  al. [12], report approaches to weight health 
outcomes in diferent subgroups along speciic equity 
dimensions. Speciic weights are developed using a will-
ingness-to-pay measure or person trade-of technique 
to weight cost-efectiveness ratios for diferent indica-
tors (e.g. severity) and age weighting functions have been 
used to weight DALYs. Inequalities in non-health fac-
tors (economic situations, political positions or occupa-
tional groups) are mentioned as important to be taken 
into account when deriving equity weights. More recent 
reviews and studies, Johri et  al. [7] and Cookson et  al. 
[13], discuss the latest thinking on methods to address 
equity concerns in CEA, such as accounting for the dis-
tribution of opportunity costs, the use of mathematical 
programming, multi-criteria decision analysis, and two 
recently developed approaches: distributional cost-efec-
tiveness analysis (DCEA) and extended cost-efectiveness 
analysis (ECEA). DCEA, developed by researchers at the 
University of York, involves two steps: irst the model-
ling of the overall social distribution of health in a setting 
and that associated with each intervention; and second, 
it evaluates the gains in health equity (or distributional 
fairness) as it trades of with total gains in health [13, 
14]. he second methodological framework, ECEA, was 
developed through the Disease Control Priority Network 
(DCPN) project [15]. his approach accounts for the dis-
tributional health consequences in addition to assessing 
the inancial risk protection (FRP) beneits of households, 
or the prevention from illness-related impoverishment 
[16]. FRP, one of the outcomes measured in ECEA, quan-
tiies the number of poverty cases averted. Illness-related 
loss of income and expenditure to seek care are the main 
causes of inancial risks that can be prevented either by 
preventing the illness or its progression or by having 
a well-structured health care system [17]. DCEA has 
mostly been applied to the high-income country setting 
of the United Kingdom, while ECEA has generally been 
used for low- and middle-income countries where there 
is a higher risk of sufering from disease-related impov-
erishment, although each approach could be applied to 
either setting. Most reviews conclude that the established 
methods are either not commonly used or not fully satis-
factory. Further noted, challenges that were highlighted 
were the selection of “equity-relevant” characteristics for 
each setting and disease and the di culty of prioritizing 
those characteristics.
he purpose of this review is two-fold. Firstly to 
develop a comprehensive list of equity-relevant indica-
tors based on the equity criteria contained within the 
Guidance on Priority Setting in Health Care (GPS-
Health) by Norheim et al. [18]. he GPS-Health check-
list consists of broad criteria that are theoretical rather 
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than operational. hus, our aim was to use this check-
list to develop speciic equity indicators that could be 
operationalized to help researchers and decision-mak-
ers navigate through equity-relevant characteristics 
that can be incorporated in CEAs. Secondly to assess 
the extent to which the mapped indicators were incor-
porated in the analysis of published CEAs, and whether 
they were relected in the results or also included as an 
explicit equity objective of the study. It provides a form 
of assessment tool to evaluate equity in existing cost-
efectiveness studies.
We chose to focus our study on cost-efectiveness anal-
yses of rotavirus vaccines in low- and middle-income 
countries. he use of CEA has been central in many 
countries to decisions regarding the introduction of vac-
cines in national immunization programs. he adoption 
of second wave vaccines such as rotavirus, human papil-
lomavirus (HPV), pneumococcal conjugate, Hepatitis B, 
and Haemophilus influenzae type B vaccines have been 
less straightforward than traditional childhood vaccines. 
Compared to the irst wave of mass vaccination (vac-
cines against measles, diphtheria, tetanus and pertussis), 
the second-wave vaccines are more costly and are less 
consistently cost efective [19]. Consequently, the costs 
and beneits of new vaccines must be carefully weighed, 
especially in low-resource settings [14]. Understanding 
the equity impacts of new vaccine introduction is also an 
important consideration. For example, Gavi, the Global 
Alliance for Vaccines and Immunizations 2016–2020 
strategy addresses within-country inequities in immuni-
zation through the use of an equity indicator measured 
as the diference in coverage between the wealthiest and 
poorest wealth quintiles of a country [20].
Rotavirus vaccination, recommended by the World 
Health Organization for all countries, has witnessed a 
partial uptake in LMICs despite demonstrated cost-efec-
tiveness [21]. Two vaccines are currently licensed for the 
prevention of rotavirus, which accounts for 35–55% of 
gastroenteritis, 40% of diarrhea-related hospitalization in 
children aged less than 5 years and has a mortality rate of 
3.4% worldwide [22, 23]. he choice of introducing rota-
virus vaccine, or any vaccine, in a LMIC is usually driven 
by complicated decision process including considera-
tions such as disease burden, concerns about healthcare 
spending, and vaccine program costs. So far, rotavirus 
vaccine has been introduced in 93 countries and 23 are 
planning its introduction. he 76 remaining countries 
have not introduced the vaccine yet and account for 32% 
of the population worldwide [24].
Results of this study ofer important insights into the 
equity indicators relevant for vaccine CEAs, in addition 
to reviewing the extent to which indicators are incorpo-
rated within CEA.
Methods
he methodology of this study has three parts: mapping 
of equity indicators, systematic literature search and the 
assessment of the selected studies with regards to their 
incorporation of equity.
Equity indicators mapping
he GPS-Health checklist [18] (Additional ile 1: Appen-
dix A) was developed via a thorough search of the lit-
erature and a series of consultations and is a recent and 
comprehensive guidance for looking at equity in health 
priority setting. Joining the point of views of both sci-
entists and decision makers, the criteria in the checklist 
were divided into three categories: disease and interven-
tion criteria, criteria related to characteristics of social 
groups, criteria related to protection against the financial 
and social effects of ill health.
Each of the ten criteria was entered as search keywords 
and combined with the following additional keywords: 
cost-efectiveness, priority setting, decision-making, 
equity, health and health care. Pubmed/MEDLINE and 
EconLit were used and the exercise was carried out in 
February 2017. he process is summarized in Fig. 1 and 
the search strategy is in Additional ile  2: Appendix B. 
he articles identiied were screened for the inclusion 
of the indicator or a related indicator and methods were 
interpreted. As a irst step, for each criterion, candidate 
indicators of equity were selected and listed in light of 
the deinitions and examples provided by the original 
checklist. After developing this list, the catalogued indi-
cators were reviewed and discussed by NC, MB and KD 
for speciic application to vaccines, rather than more 
broadly for all interventions, as outlined in the original 
checklist. In a third step the indicators were subjected to 
a inal selection through discussion amongst the authors: 
NC and MB, and then by NC, AM and KD. he indica-
tors deemed not related to equity as applied to vaccines 
were removed. A reinement followed to adapt the indi-
cators to childhood vaccines for this particular case 
study. Productivity loss, for example, was designated as 
productivity loss of caregivers instead of patients to make 
it applicable to childhood vaccines.
Systematic review
We used studies identiied from a published systematic 
review on economic evaluations of rotavirus vaccine in 
low- and middle-income countries by Carvalho et al. [25]. 
From the studies included in the inal review (n = 66), the 
economic evaluations described as CEA were retained 
(n = 60) and the rest were discarded (n = 6).
Although equity has not been considered an integral 
component of CEA until very recently with the new 
methodological developments, important reviews on the 
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concepts and principles of equity in health [11, 26] have 
been published in the 20th century. By selecting a time 
frame between 2000 and 2017, we aimed to cover the 
entire period in which equity could have been taken into 
account in CEAs. Studies were included if they met the 
following inclusion criteria: (1) published between Janu-
ary 2000 and February 2017, (2) peer reviewed articles (3) 
focused on one or more LMICs, (4) target population of 
children under 5, (5) intervention is any rotavirus vaccine 
delivered in any manner.
Duplicate citations were removed and all remain-
ing papers were screened based on title and abstract. 
Non-English language papers included after abstract 
review were translated to English (n = 4). We followed 
the PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-analysis) guidelines and checklist for 
the review [27].
Data extraction
Studies included in the systematic review were assessed 
for the incorporation of equity considerations based on 
the indicators identiied in the irst step of the methods. 
In a irst screening, for each equity indicator, we consid-
ered the following: (1) whether the article mentions the 
indicator; (2) whether the article incorporates the indica-
tor in its analysis and results, and (3) whether the indi-
cator is neither mentioned nor incorporated. A second 
screening focused on how the indicators were included 
in the study: (1) indicators included in input, (2) indica-
tors shown in output, (3) equity framed in study objec-
tive. he input refers to the parameters included in the 
evaluation while the output deals with the results of the 
evaluation. Framing equity refers to having in the study 
an explicit statement of integrating distributional con-
cerns in the analysis. A descriptive analysis followed.
Screening was performed by one reviewer (MB). A 
consistency check was performed by second reviewer 
(NC) who extracted data independently from a 10% ran-
dom sample of articles from the 60 studies identiied.
Results
Attribution of indicators
he equity indicators developed are summarized along-
side the general GPS-Health checklist from Norheim 
et al. [18] in Table 1.
Disease and intervention criteria
his group was formed of three criteria: (1) Severity, (2) 
realization of potential, and (3) past health loss.
Severity was assigned two indicators: irstly, severity 
of illness at the individual level, commonly considered 
as a measure to relect the level of need, conveys that for 
some treatments diferent disease severities would incur 
diferent costs and results in diferent beneits [28]. Sec-
ondly, age distribution of the disease, which relects dif-
ferences in severity according to age: children less than 
6  months of age are protected by maternal antibodies 
and those between 6 and 12  months are more likely to 
be hospitalized due to rotavirus infections [29]. Includ-
ing an age distribution of rotavirus illness in the study for 
each of the disease outcomes (e.g. out-patients, hospi-
talizations and deaths) accounts for the diferent possible 
scenarios according to age. Diferent age groups have dif-
ferent risks of illness and deaths, and incur diverse costs. 
Final health status was the indicator attributed to reali-
zation of potential. It relects the capacity or potential to 
beneit from a certain treatment or intervention [30, 31].
Fig. 1 Steps of indicators’ mapping. *Norheim et al.’s criteria being: Severity, realization of potential, past health loss, socioeconomic status, area of 
living, gender, race, ethnicity, religion, sexual orientation, economic productivity, care for others and catastrophic health expenditure
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he third criteria, past health loss, was attributed the 
indicator presence of comorbidities, whether chronic dis-
eases or other health conditions. It highlights the poten-
tial special value of an intervention if it targets a group 
that has sufered signiicant past health loss [32].
Criteria related to characteristics of social groups
Four criteria were presented in this group:(1) Socioeco-
nomic status, (2) Geographic location, (3) Gender, (4) 
Race, Ethnicity, Religion and Sexual orientation.
hree indicators were mapped to Socioeconomic sta-
tus: Household income, Education and Relative coverage. 
Household income—encompassing wealth level, occupa-
tion, tenure and socioeconomic indices—and Education 
are two relevant indicators of socioeconomic position 
related to health and vaccination status. Education, at the 
individual level, is a relevant factor for vaccination as it 
impacts parents’ decision and eforts to vaccinate their 
children [33]. Relative coverage was highlighted as Gavi’s 
principal equity indicator and a measure used to relect 
the extent to which a certain programs’ coverage reaches 
those at higher risk. Relative coverage is a “derived indi-
cator” based on wealth ratios and is calculated by the 
diferences in coverage between the richest and the poor-
est quintiles [34, 35].
Area of living refers to the geographic location and 
captures the contribution of geographic inequalities in 
health and access to health care [36]. his indicator con-
sidered rural/urban diferences or state/provinces bound-
aries, depending on the study. Race, Ethnicity, Religion 
and Sexual orientation were separated into four disparate 
indicators: Race, Ethnicity and Religion to acknowledge 
that some disadvantaged groups might need to be given 
a certain level of attention and priority [37] and Sexual 
orientation was found to be particularly relevant for a 
certain set of diseases (e.g. sexually transmitted diseases) 
[38].
Criteria related to protection against the inancial and social 
efects of ill health
his group’s three criteria (8) Economic productivity, (9) 
Care for others, and (10) Catastrophic health expenditure 
were assigned ive indicators. Two indicators were dis-
tinguished for Economic productivity: he irst indicator 
is Loss of productivity, whether it relates to the informal 
caregiver’s productivity or patient’s productivity, it has an 
Table 1 Summary of the GPS-Health checklist and mapped indicators
a GPS-Health Equity checklist developed by Norheim et al. [18]
b Indicators developed by authors
GPS-Health Equity  checklista Indicatorsb Deinition
Group 1: Disease and intervention criteria
 Severity Severity of illness at the individual level Mild/moderate/severe
Age distribution of the disease Disease incidence by age group
 Realization of potential Final health status Health status after treatment showing treatment 
benefit capacity
 Past health loss Presence of comorbidities Presence of other diseases or conditions with the 
studied disease
Group 2: Criteria related to characteristics of social groups
 Socioeconomic status Household income level Wealth level, occupation, and socioeconomic indices
Relative coverage Difference in coverage between the richest and 
poorest quintile
Education Education level of patients or parents
 Area of living Geographic location Urban/rural; by province or by state
 Gender Sex at birth Male/Female
 Race, ethnicity, religion and sexual orientation Race Having certain physical characteristics
Ethnicity Belonging to a social group
Religion Belonging to a religious group
Sexual orientation Homo/Heterosexual
Group 3: Criteria related to protection against the financial effect of ill health
 Economic productivity Loss of productivity Productivity lost due to illness
Age Age-weighting of DALYs
 Care for others Number of dependent persons Are children or elderly depending on the patient?
 Catastrophic health expenditure Financial risk protection Protection against catastrophic spending
Reliance on OOP expenditure OOP spending due to illness for treatment or care
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important inancial impact on the household [39]. Loss of 
productivity is measured through the foregone or incre-
mental income, absenteeism and presenteeism. he sec-
ond is Age, accounting for average age of the population 
beneiting from the treatment (e.g. treatment targeting 
children, adults or retired). DALYs age-weighting rep-
resent, to a certain extent, the economic productivity of 
an individual, given very young and older ages depend 
physically, emotionally and inancially on individuals 
belonging to the “economically productive” ages. hey 
are thus assigned lower weights [40, 41]. A continuous 
debate revolves around this indicator: critics question 
why age only was given an important social value and not 
any other socioeconomic component. Moreover, Years of 
life lost (YLL) favors the young, so age-weighting DALYs 
would only double this emphasis [42]. It is worth men-
tioning that the WHO cost-efectiveness guidelines pub-
lished in 2000 presented its result with and without age 
weighting and the one published in 2010 omitted the 
inclusion of age weighting [43]. he criterion “Care for 
others” was assigned the indicator “Number of depend-
ent persons” (e.g. children or elderly). he value of the 
intervention might increase with the increase of the 
number of persons depending on the patient. Two indi-
cators were mapped to Catastrophic health expenditure: 
he Reliance on of Out-Of-Pocket (OOP) expenditure 
and Financial Risk Protection (FRP), both of major rele-
vance in LMIC’s which may have poor coverage of health 
insurance [44]. he reliance of OOP expenditure relects 
the weight of reliance on private funds to pay for an 
intervention. It can be OOP as a percentage of consump-
tion, or the quantiication of the amount spent OOP on 
certain health services.
Financial risk protection addresses illness-related 
impoverishment. It measures the extent to which an 
intervention protects a household from catastrophic 
expenditure leading to poverty and relects inequalities in 
income and wealth [45].
Articles included in the systematic review
he study selection process is presented in Fig. 1. A total 
of 529 articles were identiied after duplicate removal and 
screened for inclusion and exclusion criteria based on 
title and abstract. 103 full text studies were read by two 
reviewers [25] and 44 articles were excluded. In the inal 
review, 60 CEAs were included (Fig. 2).
he articles were published between 2005 and 2016, 
with rotavirus vaccine introduction starting in 2006. 52 
articles (87%) focused on individual LMICs around the 
world and 8 (13%) studied groups of countries. Even 
though a signiicant portion of studies focused on Asian 
countries (23 articles—44% of the single country articles), 
the continent has the lowest uptake of rotavirus vaccine 
[46].
Application of indicators to rotavirus vaccine
he articles were assessed by MB and the consistency 
check run by NC resulted in 97% agreement across all 
categories.
Of the 18 mapped indicators, two were judged to be 
less relevant to the speciic case of rotavirus vaccine due 
to the disease characteristic and the intervention’s tar-
geted population: (1) Final health status: the sick chil-
dren either died or recovered from the infection, no 
other health status could be attained and (2) Number of 
dependent persons: being a childhood vaccine, the indi-
viduals contracting the virus are not caring for any other 
persons but are cared for; and ive indicators were not 
taken into account in any of the articles: (3) Education, 
(4) Race, (5) Ethnicity, (6) Religion, (7) Sexual Orienta-
tion. he eleven remaining criteria were relevant and 
appeared in the identiied articles.
Severity
Severity of illness at the individual level was taken into 
account in 45 (75%) of the included articles by categoriz-
ing cases into three severity levels: mild, moderate, and 
severe. he levels were deined in terms of degree of care 
needed, whether no care, outpatient care or hospitaliza-
tion respectively was required. he results were all pre-
sented as events and costs averted per degree of severity. 
he remaining 15, forming 25% of the studies, did not 
capture difering levels of disease severity. It is worth 
mentioning that 3 (20%) of these remaining studies were 
Extended Cost-Efectiveness Analysis, 5 (33%) consti-
tuted studies dealing with groups of countries (whether 
Gavi-eligible countries or developing countries) and only 
7 (47%) were single-country studies.
Age distribution of the disease
Age distribution was incorporated in 42 articles (70%). In 
addition to incorporating it in the input, two studies (3%) 
relected the diferences in the output as cases averted 
per age. An example can be found in Martí et al. [47].
Presence of comorbidities
Two comorbidities were mentioned within the rotavirus 
CEAs: malnutrition, mentioned nine times (15%), and 
the presence of other diseases, mainly pneumonia and 
HIV, referred to twice (3%).
Malnutrition was incorporated in the analysis of 3 arti-
cles (5%). Two articles used proxies to estimate the dis-
tribution of rotavirus mortality across wealth quintiles 
representing higher physical susceptibility as measured 
by weight for age Z scores [48, 49]. he third developed 
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an evidence-based individual risk index to estimate the 
relative distribution of mortality within the region-sex 
populations based on nutritional status and access to 
basic care for diarrheal disease.
he presence of chronic diseases also afects the input 
parameters. Two articles (3%) acknowledged special con-
ditions of sub-groups and thus excluded children with 
pneumonia or HIV from their analysis.
Household income level
Household income was mentioned since 2006 as an 
important criterion to be taken into account when 
performing CEA, but it is not until 2012 that studies 
began dividing their results per wealth quintile. 5 (8%) 
of the identiied articles presented their results accord-
ingly. Results, in terms of incremental cost-efective-
ness ratios (ICERs) and deaths averted, from the same 
country were quite diferent between wealth quintiles: 
the richest quintiles had signiicantly higher ICERs per 
DALY averted and the poorest had more deaths averted 
with the implementation of the intervention. he Rhe-
ingans study [49] illustrates these diferences: the rich-
est quintile’s ICER (180$ per DALY averted) in India 
was more than triple the poorest quintile’s ICER (55$ 
per DALY averted).
Relative coverage
An adjustment factor for relative coverage was applied 
to the coverage estimates to account for the likelihood 
that children at the highest risk of dying from rotavirus 
disease are less likely to be vaccinated [50]. he inclu-
sion of relative coverage in the CEAs increased over 
time (Fig.  3a) with a total of 18 articles from the 60 
(30%) including this indicator. Clarke et  al. [51] dem-
onstrated that relative coverage is a key driver in CEA 
through sensitivity analyses (along with the herd efect 
multiplier).
Fig. 2 Literature search flow diagram. Flow diagram adapted from “Capturing Budget Impact Considerations Within Economic Evaluations” by 
Carvalho et al. [25]. a Including one article in Russian for which full text could not be obtained
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Geographic location
16 (27%) of the identiied articles included geographic 
location in the analysis. For some countries, important 
diferences in ICERs were detected between diferent 
provinces. he inclusion of this indicator was noted to 
increase over time (Fig. 3b).
Two approaches were used to incorporate the geo-
graphic measure: Out of the 27% taking into consid-
eration geographic location, 13 (81%) of the articles 
accounted for diferences in costs between rural and 
urban areas and some generated weights for that pur-
pose. he remaining 3 articles (19%) took a step further 
to incorporate (along with costs) incidence and coverage 
variations. his is clearly shown in Rheingans et al. [52] 
where the costs, beneits and ICERs were calculated for 
every region of India.
Sex at birth
Sex at birth (male/female) was only incorporated a few 
times (5%). Wilopo et  al. [53] assumed diferent rota-
virus-speciic mortality rates for males and females. 
Megiddo et  al. [33] incorporated a stochastic function 
based on several characteristics (one of which is sex) by 
which children contract the disease and Rheingans et al. 
[54] modeled a unit of analysis deined as equal to: geo-
graphic area × wealth quintile × sex.
Loss of productivity
In the childhood vaccines setting, the productivity loss 
accounted for is that of the caregiver. Caregiver produc-
tivity was often mentioned in the methods (44 times; 
73%), however only 27 articles (45%) incorporated the 
caregiver’s lost income in the societal costs.
a
b
c
Fig. 3 Trends over time in the number of articles incorporating a relative coverage, b Geographic location, and c age weighting. *Percentage of 
articles out of total number of articles published during the specified period of time
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Age
he impact of age on productivity was taken into 
account by age weighting of DALYs. 26 articles (43%) 
age weighted DALYs but this method is shown to be 
decreasing over time (Fig. 3c).
Financial risk protection (FRP)
Health gains and FRP were taken into account in all of 
the evaluations categorized as extended cost-efective-
ness analysis (ECEA), given it is an integral part of the 
approach. Within the rotavirus CEA articles, the impor-
tance of inancial risk protection was acknowledged in 
2006 by Isakbaeva et al. [55] but the actual incorporation 
of FRP is relatively new and was performed in one study 
in 2013 [56] and two others in 2015 [48, 57].
Reliance on OOP expenditure
Out of 60 articles, 35 (58%) considered a societal per-
spective and included in the costs’ calculations the 
OOP expenditure incurred by the patients’ households. 
he costs averted were separated between government 
and societal perspective.
Equity framing in study objective
he assessment conducted showed that, out of the 
selected articles, all incorporated at least one equity 
indicator as a parameter of the cost efectiveness anal-
ysis and 54 (90%) articles incorporated at least two. 
However, not all the studies explicitly mentioned equity 
as a study objective. Out of all the selected articles, 
only 10 (17%) explicitly mentioned equity in their study 
objective, with an increasing trend over time: 10% out 
of studies published between 2005 and 2008 and 28% 
out of those published between 2013 and 2016 explic-
itly had an equity objective (Fig. 4).
Overall, 6 articles stated that they considered the dif-
ferences between urban and rural communities with 
the aim of achieving higher levels of equity, 3 articles 
considered wealth quintile, 3 inancial risk protection, 
1 societal perspective and 1 sex at birth. Also, 3 articles 
mentioned distributional consequences as a general 
objective not related to a speciic indicator.
Incorporation of indicators in input and output
Indicators were all incorporated in economic evalu-
ation inputs, but in 48 articles (80%), they were also 
relected in the economic evaluation results. Results 
were diferentiated with regards to 6 indicators: severity 
of illness, reliance on OOP expenditure, FRP, household 
income, age distribution of the disease and geographic 
location. Severity of illness, shown in the output of 33 
articles (55%), divided the costs per level of severity: 
per outpatient visit, per hospitalization and per death. 
Reliance on OOP expenditure, shown in the output of 
23 articles (38%), provides ICERs for a societal perspec-
tive and/or the OOP expenditure averted per infection 
episode. For household income, 4 articles (7%) present 
results diferentiated by wealth quintile, such as rotavi-
rus cases or deaths averted, private expenditure averted 
or ICER ($/DALY) averted by wealth quintile. FRP con-
stitutes a speciic case as it is designed to be part of the 
outcome. It focuses on the number of cases of poverty 
averted instead of costs per health gains or per death 
averted. Geographic location (in 3 articles—5%) cat-
egorizes the results by state, province or urban/rural. 
Lastly, Age distribution of the disease, shown in the 
outcome of 2 articles (3%), shows the number of rotavi-
rus infection cases averted by age.
Results are summarized in Table  2, the full data table 
can be found in Additional ile  3: Appendix C, and the 
proportion of each indicator included in the articles over 
time in Additional ile 4: Appendix D.
Discussion
An operational set of indicators for formally assessing the 
types of equity incorporated in cost-efectiveness analy-
sis was developed based on the GPS-Health Equity cri-
teria. his mapping process gathers equity indicators in 
one checklist. It allows decision-makers to go through 
functional equity-relevant characteristics and research-
ers to explore the extent to which equity considerations 
are captured within the economic evaluation literature. 
he process of identifying the indicators included a sys-
tematic review of the criteria listed in the GPS-Health 
checklist and review of proposed indicators. he results 
of this process allows for practical use in assessing 
Fig. 4 Equity concern framed in study objective over time. 
*Percentage of articles out of total number of articles published 
during the specified period of time
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Table 2 Summary of indings
a n = 60
b All the studies having mentioned equity in their study objectives have incorporated at least one indicator in their analysis
Indicator Number incorporating 
the indicator 
into  analysisa
Indicator 
framed in study 
 objectivea
Summary of methods used 
and example
Number of articles 
incorporating equity indicator 
in  outcomea,b
Severity of illness at the indi-
vidual level
45 (75%) 0 Results split into severity 
subgroups
Example: number of events 
and costs averted for inpa-
tients and outpatients
33 (55%)
Age distribution of the disease 42 (70%) 0 Including an age distribution 
function showing the inci-
dence and costs by age
2 (3%)
Presence of comorbidities 3 (5%) 0 By calculating proxies for physi-
cal susceptibility of being 
infected
Example: weighting for age 
Z-score [49] or establishing 
an individual risk model [54]
0
Household income level 5 (8%) 3 (5%) Results divided by wealth 
quintile
Example: dividing each of the 
following by Wealth Quintile: 
Number of deaths averted 
[56], private expenditure 
averted [48], or estimated 
burden due to RV illness [54]
4 (7%)
Relative coverage 18 (30%) 0 Including an adjustment factor 
for effective coverage
Example: Diop et al. [50] 
divided the coverage in the 
lowest quintile by the cover-
age in the entire population
0
Geographic location 16 (27%) 6 (10%) Results differentiated between 
rural and urban or divided by 
state or province
Example: deaths averted, OOP 
expenditure averted and gov-
ernment costs for each rural 
and urban settings [33]
3 (5%)
Sex at birth 3 (5%) 1 (1.6%) Input data are differentiated 
by sex
Example: population data by 
sex, disease incidence and 
case-fatality rates by sex [53]
0
Loss of productivity 27 (45%) 0 Including costs due to caretak-
ers taking time off from work 
in the calculation of costs 
incurred by society
0
Age 26 (43%) 0 DALYs age weighting 0
Financial risk protection (FRP) 3 (5%) 3 (5%) Through an Extended Cost-
Effectiveness analysis
Example: calculating a money-
metric value of FRP provided 
by the program [56]
3 (5%)
Reliance on OOP expenditure 35 (58%) 1 (1.6%) Differentiating the costs 
incurred by society (societal 
perspective)
Example: calculating the medi-
cal and non-medical costs 
incurred [47]
23 (38%)
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published cost-efectiveness analyses. By reining the 
broad concepts that comprise the criteria, the resulting 
indicators are foreseen to have two general applications. 
Firstly, at the decision-making level, the equity indicator 
mapping provides guidance to policy makers when mak-
ing resource allocation decisions at the local level. he 
deinition and selection of the appropriate indicators is 
unlikely to be a one-size-its-all solution, but the devel-
oped indicators provide a start to developing a compre-
hensive list to select from in light of national health goals. 
he relevance of each indicator is likely to depend on the 
context and the speciic populations and interventions of 
interest [58]. For instance, taking into account the pres-
ence of comorbidities appeared to be context-speciic. 
Some illnesses might be relevant in one setting but not 
in another. For example, HIV as comorbidity for child-
hood rotavirus disease was taken into account in South 
Africa given the high burden of HIV, while malnutrition 
was considered as a comorbidity in a Yemen-based analy-
sis. hus, the list of indicators is a tool that can be used 
when designing studies that incorporate equity dimen-
sions in economic evaluations. Secondly, for analysts, 
the indicators can be used to monitor the incorporation 
of equity in cost-efectiveness analyses, as was done in 
this case for rotavirus vaccine CEAs. heir application 
to other diseases and settings is likely to prove useful. It 
also highlights equity considerations that warrant further 
evaluation and development, including needed methodo-
logical advancement.
he analysis of the set of articles identiied through the 
systematic review distinguished two indicators predomi-
nantly included in the existing economic evaluations: 
severity of illness and age. Severity of illness at the indi-
vidual level is widely accepted as primary importance to 
be adopted with the efectiveness of treatment in diverse 
settings. Use of severity as a priority indicator has been 
seen in countries such as South Korea [59] and Uganda 
[60], and has established signiicance in developed coun-
tries through its use in many National Health Services 
(such as the Norwegian, Finnish, French, Spanish, Ger-
man and Swedish NHS) [61]. Its major presence (75% of 
the identiied articles) might be due to its relatively easy 
measurement and link with measurable outcomes with 
associated costs and health efects. Age was considered 
through two separate indicators even though its inclu-
sion on equity grounds is still a matter of controversy. 
Its wide inclusion may relect the relative ease of incor-
porating it either via an age distribution function of dis-
ease cases and death, or through the age weighting of 
DALYs. Although age weighting of DALYs, relecting the 
higher proile of productivity of young adults, has been 
criticized and removed from the WHO cost-efectiveness 
guidelines, its level of use (albeit less frequent) suggests 
that some researchers might still regard its relevance. 
Notably, age is also indicative of severity, explaining the 
high percentage of inclusion of both in CE studies.
Nonetheless, despite the extensive use of these two 
indicators in the included CEAs, neither indicator was 
explicitly included in the studies with a speciic equity 
objective tied to these indicators as an equity concern. 
Few articles formally included equity considerations with 
distribution purposes. hose that did focused on difer-
ences across geographic areas, wealth groups and sex at 
birth, and considered the impact of the intervention on 
inancial risk protection, and from a societal perspec-
tive. hey all presented results diferentiated according 
to the indicator, showing the extent to which speciic 
groups would beneit from the vaccine. It is worth men-
tioning that 30% of those articles having equity as a 
prime objective followed an extended cost-efectiveness 
approach, speciically focusing on distributional conse-
quences across distinct strata of populations and medical 
impoverishment.
When considering health equity indicators, data limi-
tations are relevant, especially when researching low-
income countries lacking basic health information 
systems [13]. Data availability is also likely to afect the 
choice of indicators.
Several research groups are working on establish-
ing and disseminating new methods, such as ECEA or 
DCEA, that prescribe combining multiple equity relevant 
traits into a single social welfare function. However, the 
literature review indings remain disaggregated per indi-
cator, as no study so far had presented indings in terms 
of cost-efectiveness of several equity-related indica-
tors together. Results are also contextually bound as the 
choice of indicators stems from the need of a speciic 
country or country’s wealth level. We noted that few of 
the included studies simultaneously considered multiple 
equity criteria. For example, several studies integrating 
FRP, an important indicator linked to households’ cata-
strophic health expenditure along with wealth quintiles, 
omitted the inclusion of severity of illness [15, 48, 56]. A 
similar matter also applied to geographic location [33, 
54] and household income [49] where usually only one 
dimension was formally incorporated in the analysis. 
his is likely due to being methodologically demanding 
by introducing a higher level of complexity to the analy-
sis, which may also be di cult for end users to process. It 
is also possible that data limitations become more impor-
tant with the inclusion of multiple indicators, and with 
the consideration of more indicators, the level of uncer-
tainty in estimates will also increase.
It is important to note that our results are limited by the 
indicator checklist established and by the case study cho-
sen (CEA of rotavirus vaccines in LMICs). hroughout 
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the research, the inclusion or rejection of some indicators 
created dilemmas on whether they are, irstly, directly 
relevant to equity and secondly appropriate to our case 
study and context. Herd immunity constitutes an exam-
ple of equity relevance problem. While herd immunity 
could be considered related to equity if additional protec-
tion is conferred upon marginalized groups less likely to 
be vaccinated, this is not always the case, and following 
group discussions, this indicator was removed from the 
list.
As it is unlikely that a single list of indicators would 
apply uniformly across settings and interventions, these 
indicators will need to be modiied and selected to suit 
the evaluation of other populations and interventions. 
Whilst the indicators are likely to have broad relevance 
for many conditions it is important to note that they were 
developed speciically for application to this vaccination 
example.
A further step might be the assessment of other child-
hood vaccines CEAs in order to monitor and compare 
the usefulness and applicability of the indicators. Further 
work can be performed with the list of equity indicators 
to establish metrics translating the equity dimension as 
was done with FRP.
Conclusion
he list of equity indicators developed through this study 
allows for a systematic assessment of the incorporation of 
equity dimensions in CEA of childhood vaccines. It also 
operationalizes Norheim et  al.’s GPS-Health checklist. 
his work highlights the lack of articles which formally 
include equity considerations with distribution purposes.
Areas warranting consideration on the basis of existing 
evidence have been highlighted namely: FRP, severity of 
illness, and reliance on OOP expenditure. Areas necessi-
tating more research have likewise been identiied such 
as presence of comorbidities and additional indirect eco-
nomic beneits. When many indicators were considered, 
results were often presented in a disaggregated form. 
here is a need to develop methodologies relecting the 
equity indicator not only in the input but also in the out-
put of an economic evaluation and combining indicators 
within a single output. A single output might provide 
more direct comparisons and general conclusions can 
be drawn taking into account all the subsegments of the 
population. Nonetheless, this might come at the expense 
of more nuanced understandings for decision makers.
he identiied equity indicators are likely to be useful 
for the assessment of other childhood vaccines to assess 
diferences in equity consideration. It can also be applied 
to interventions beyond childhood vaccination, noting 
that changing the setting might change the focus of the 
equity dimensions and other dominant indicators might 
be noted. Our review demonstrates a growing consid-
eration of distributional issues and the expanded use of 
some indicators in cost-efectiveness analysis.
Authors’ contributions
NC conceived the study. NC developed the search strategy, inclusion and 
exclusion criteria, as well as conducted the searches. NC did initial screening 
of titles and abstracts and assessed full-text articles for inclusion in review. MB 
developed the list of equity indicators with input from NC, KD and AM. MB 
scored and abstracted data from all articles reviewed, with guidance from NC, 
KD, AM. MB and NC wrote the report with input from all authors. All authors 
read and approved the final manuscript.
Author details
1 Faculty of Economics, University of Bologna, Bologna, Italy. 2 Centre 
for Health Economics, University of York, York, UK. 3 Centre for Health Policy, 
The University of Melbourne, Melbourne, Australia. 4 Centre for Health Policy 
& Global Burden of Disease Group, School of Population and Global Health, 
University of Melbourne, Melbourne, Australia. 
Acknowledgements
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
All data generated or analysed during this study are included in this published 
article and its supplementary information files.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Funding
MB was funded by the University of Bologna International Students’ Study 
Grant. NC was funded by the University of Melbourne McKenzie Postdoctoral 
Fellowship Scheme.
The funding bodies had no role in the design of the study and collection, 
analysis, and interpretation of data and in writing the manuscript.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 14 February 2018   Accepted: 26 April 2018
References
 1. Martin CM, Kaufman T. Addressing health inequities: a case for imple-
menting primary health care. Can Fam Physician. 2008;54(11):1515–7.
Additional iles
Additional ile 1: Appendix A. Norheim Checklist.
Additional ile 2: Appendix B. Indicators search strategy.
Additional ile 3: Appendix C. Full data table of results.
Additional ile 4: Appendix D. Figure S1. Trends over time in articles 
incorporating various equity criteria. Figure S2. Average number of 
indicators included in studies over time.
Page 13 of 14Boujaoude et al. Cost Ef Resour Alloc  (2018) 16:18 
 2. O’Donnel O, van Doorslaer E, Wagstaff A, Lindelow M. Analyzing health 
equity using household survey data. The World Bank. Washington, D.C.: 
WBI Learning Resources; 2008.
 3. Braveman P, Gruskin S. Defining equity in health. J Epidemiol Community 
Health. 2003;57:254–8.
 4. Culyer AJ. Efficiency, equity and equality in health and health care. In: 
CHE Research Paper 120; 2015.
 5. Braveman P. Health disparities and health equity: concepts and measure-
ment. Annu Rev Public Health. 2006;27:167–94.
 6. Östlin P, Schrecker T, Sadana R, Bonnefoy J, Gilson L, Hertzman C, et al. 
Priorities for research on equity and health: towards an equity-focused 
health research agenda. PLoS Med. 2011;8:11.
 7. Johri M, Norheim OF. Can cost-effectiveness analysis integrate con-
cerns for equity? Systematic review. Int J Technol Assess Health Care. 
2012;28(2):125–32.
 8. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg 
D, et al. Consolidated health economic evaluation reporting standards 
(CHEERS) statement. Value Health. 2013;16(2):e1–5.
 9. Shah KK, Cookson R, Culyer AJ, Littlejohns P. NICE’s social value judge-
ments about equity in health and health care. Health Econ Policy Law. 
2013;8(2):145–65.
 10. Claxton KP, Revill P, Sculpher M, Wilkinson T, Cairns J, Briggs A. The gates 
reference case for economic evaluation. The Bill and Melinda Gates 
Foundation; 2014. p. 68.
 11. Sassi F, Archard L, Le Grand J. Equity and the economic evaluation of 
healthcare. Health Technol Assess. 2001;5(3):1–38.
 12. Hauck KS, Smith AC, Goddard M. The economics of priority setting for 
health care: a literature review. HNP Discussion Paper; 2004.
 13. Cookson R, Mirelman AJ, Griffin S, Asaria M, Dawkins B, Norheim OF, et al. 
Using cost-effectiveness analysis to address health equity concerns. Value 
Health. 2017;20(2):206–12.
 14. Asaria M, Griffin S, Cookson R. Distributional cost-effectiveness analysis: a 
tutorial. Med Decis Making. 2016;36(1):8–19.
 15. Verguet S, Laxminarayan R, Jamison DT. Universal public finance of tuber-
culosis treatment in India: an extended cost-effectiveness analysis. Health 
Econ. 2015;24(3):318–32.
 16. Verguet S, Kim JJ, Jamison DT. Extended cost-effectiveness analy-
sis for health policy assessment: a tutorial. Pharmacoeconomics. 
2016;34(9):913–23.
 17. Jamison DT. Cost-effectiveness analysis: concept and applications, vol. 4. 
Oxford: Oxford University Press; 2002.
 18. Norheim OF, Baltussen R, Johri M, Chisholm D, Nord E, Brock D, et al. 
Guidance on priority setting in health care (GPS-Health): the inclusion of 
equity criteria not captured by cost-effectiveness analysis. Cost Eff Resour 
Alloc. 2014;12:18.
 19. Glassman A, Cañón O, Silverman R. How to get cost-effectiveness analysis 
right? The case of vaccine economics in Latin America. Value Health. 
2016;19(8):913–20.
 20. Gandhi G. Charting the evolution of approaches employed by the Global 
Alliance for Vaccines and Immunizations (GAVI) to address inequities in 
access to immunization: a systematic qualitative review of GAVI policies, 
strategies and resource allocation mechanisms through an equity lens 
(1999–2014). BMC Public Health. 2015;15:1198.
 21. World Health Organization. Rotavirus Vaccines. WHO position paper—
January 2013. Wkly Epidemiol Rec. 2013;5(88):49–64.
 22. Ahs JW, Tao W, Löfgren J, Forsberg BC. Diarrheal diseases in low- and 
middle-income countries: incidence, prevention and management. Open 
Infect Dis J. 2010;4:113–24.
 23. World Health Organization: Estimated rotavirus deaths for children under 
5 years of age: 2013, 215000. http://www.who.int/immun izati on/monit 
oring _surve illan ce/burde n/estim ates/rotav irus/en/. Accessed 10 Sept 
2017.
 24. International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg 
School of Public Health. VIEW-hub. https ://www.view-hub.org. Accessed 
20 Oct 2017.
 25. Carvalho N, Jit M, Cox S, Yoong J, Hutubessy RCW. Capturing budget 
impact considerations within economic evaluations: a systematic review 
of economic evaluations of rotavirus vaccine in Low- and Middle-Income 
Countries and a proposed assessment framework. Pharmacoeconomics. 
2017. https ://doi.org/10.1007/s4027 3-017-0569-2.
 26. Whitehead M. The concepts and principles of equity and health. Int J 
Health Serv. 1991;22(3):429–45.
 27. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred 
reporting items for systematic reviews and meta-analysis: the PRISMA 
statement. PLoS Med. 2009;6(7):e1000097.
 28. Nord E. Severity of illness versus expected benefit in societal evaluation 
of healthcare interventions. Expert Rev Pharmacoecon Outcome Res. 
2001;1(1):85–92.
 29. Van Man N, Le Luan T, Trach DD, Thanh NT, Van Tu P, Long NT, et al. 
Epidemiological profile and burden of rotavirus diarrhea in Vietnam: 
5 Years of sentinel hospital surveillance, 1998–2003. J Infect Dis. 
2005;194(Suppl1):S127–32. https ://doi.org/10.1086/43150 1.
 30. Hanvoravongchai P. Health system and equity perspectives in health 
technology assessment. J Med Assoc Thai. 2008;91(Suppl 2):S74–87.
 31. Hope T. Rationing and life-saving treatments: should identifiable patients 
have higher priority? J Med Ethics. 2001;27(3):179–85.
 32. Moura FL, Goulart PR, Moura AP, Souza TS, Fonseca AB, Amendoeira 
MR. Factors associated to toxoplasmosis-related knowledge among 
pregnant women attending public health services in the municipal-
ity of Niteroi, Rio de Janeiro, Brazil, 2013–2015. Epidemiol Serv Saude. 
2016;25(3):655–61.
 33. Megiddo I, Colson AR, Nandi A, Chatterjee S, Prinja S, Khera A, et al. 
Analysis of the universal immunization programme and introduction 
of a rotavirus vaccine in India with IndiaSim. Vaccine. 2014;32(Suppl 
1):A151–61. https ://doi.org/10.5123/S1679 -49742 01600 03000 22.
 34. Arsenault C, Harper S, Nandi A, Rodriguez JM, Hansen PM, Johri M. An 
equity dashboard to monitor vaccination coverage. Bull World Health 
Organ. 2017;95(2):128–34.
 35. Uruena A, Pippo T, Betelu MS, Virgilio F, Hernandez L, Giglio N, et al. 
Cost-effectiveness analysis of rotavirus vaccination in Argentina. Vaccine. 
2015;33(Suppl 1):A126–34.
 36. Quintal C. Aversion to geographic inequality and geographic variation in 
preferences in the context of healthcare. Appl Health Econ Health Policy. 
2009;7(2):121–36.
 37. Devlin N, Sussex J. Incorporating multiple criteria in HTA: methods and 
processes. Office of Health Economics; 2011. https ://www.ohe.org/publi 
catio ns/incor porat ing-multi ple-crite ria-hta-metho ds-and-proce sses. 
Accessed 20 June 2017.
 38. Newman PA, Logie CH, Doukas N, Asakura K. HPV vaccine acceptability 
among men: a systematic review and meta-analysis. Sex Transm Infect. 
2013;89(7):568–74.
 39. Krol M, Brouwer W. How to estimate productivity costs in economic 
evaluations. Pharmacoeconomics. 2014;32(4):335–44. https ://doi.
org/10.1007/s4027 3-014-0132-3.
 40. World Health Organization. WHO methods and data sources for global 
burden of disease estimates 2000–2015. In: Global Health Estimates Tech-
nical Paper WHO/HIS/IER/GHE/2016.2. http://www.who.int/healt hinfo /
stati stics /LT_metho d.pdf. Accessed 21 Dec 2017.
 41. Donev D, Zaletel-Kragelj L, Bjegovic V, Burazeri G. Measuring the burden 
of disease: disability adjusted life years (DALY) [online]. Available: http://
www.mf.uni-lj.si/dokum enti/6b695 fc938 5e3e2 ab8fb 41ec7 d3466 0d.pdf. 
Accessed 20 Dec 2017.
 42. Murray C, Acharya A. Age weights and discounting in health gaps 
reconsidered. In: Murray CJL, Solomon JA, Mathers CD, Lopez AD, editors. 
Summary measures of population health: concepts, ethics, measurement 
and applications. Geneva: World Health Organization; 2002. p. 677–84.
 43. Chen A, Jacobsen KH, Deshmukh AA, Cantor SB. The evolution of the 
disability-adjusted life year (DALY). SocioEcon Plan Sci. 2015;49:10–5.
 44. Xu K, Evans DB, Kawabata K, Zeramdini R, Klavus J, Murray CJL. House-
hold catastrophic health expenditure: a multicountry analysis. Lancet. 
2003;362(9378):111–7.
 45. Saksena P, Hsu J, Evans DB. Financial risk protection and universal 
health coverage: evidence and measurement challenges. PLoS Med. 
2014;11(9):e1001701.
 46. Kirkwood CD, Steele AD. Rotavirus vaccine will have an impact in Asia. 
PLoS Med. 2017;14(5):e1002298.
 47. Marti SG, Alcaraz A, Valanzasca P, McMullen M, Standaert B, Garay U, 
et al. Cost effectiveness evaluation of a rotavirus vaccination program in 
Argentina. Vaccine. 2015;33(42):5684–90.
 48. Pecenka CJ, Johansson KA, Memirie ST, Jamison DT, Verguet S. Health 
gains and financial risk protection: an extended cost-effectiveness 
Page 14 of 14Boujaoude et al. Cost Ef Resour Alloc  (2018) 16:18 
•
 
fast, convenient online submission
 
•
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  
At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research  ?  Choose BMC and benefit from: 
analysis of treatment and prevention of diarrhoea in Ethiopia. BMJ Open. 
2015;5(4):e006402.
 49. Rheingans R, Atherly D, Anderson J. Distributional impact of rotavirus 
vaccination in 25 GAVI countries: estimating disparities in benefits and 
cost-effectiveness. Vaccine. 2012;30(Suppl 1):A15–23.
 50. Diop A, Atherly D, Faye A, Lamine Sall F, Clark AD, Nadiel L, et al. Estimated 
impact and cost-effectiveness of rotavirus vaccination in Senegal: a 
country-led analysis. Vaccine. 2015;33(Suppl 1):A119–25.
 51. Clark A, Jauregui B, Griffiths U, Janusz CB, Bolanos-Sierra B, Hajjeh R, 
Andrus JK, Sanderson C. TRIVAC decision-support model for evaluating 
the cost-effectiveness of Haemophilus influenzae type b, pneumococcal 
and rotavirus vaccination. Vaccine. 2013;31(Suppl 3):C19–29.
 52. Rheingans R, Amaya M, Anderson JD, Chakraborty P, Atem J. Systematic 
review of the economic value of diarrheal vaccines. Hum Vaccin Immu-
nother. 2014;10(6):1582–94.
 53. Wilopo SA, Kilgore P, Kosen S, Soenarto Y, Aminah S, Cahyono A, Ulfa M, 
Tholib A. Economic evaluation of a routine rotavirus vaccination pro-
gramme in Indonesia. Vaccine. 2009;27(Suppl 5):F67–74.
 54. Rheingans R. Anderson JDt, Anderson B, Chakraborty P, Atherly D, 
Pindolia D. Estimated impact and cost-effectiveness of rotavirus vaccina-
tion in India: effects of geographic and economic disparities. Vaccine. 
2014;32(Suppl1):A140–50.
 55. Isakbaeva ET, Musabaev E, Antil L, Rheingans R, Juraev R, Glass RI, et al. 
Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine. Vac-
cine. 2007;25(2):373–80.
 56. Verguet S, Murphy S, Anderson B, Johansson KA, Glass R, Rheingans R. 
Public finance of rotavirus vaccination in India and Ethiopia: an extended 
cost-effectiveness analysis. Vaccine. 2013;31(42):4902–10.
 57. Verguet S, Olson ZD, Babigumira JB, Desalegn D, Johansson KA, Kruk ME, 
Levin CE, Nugent RA, Pecenka C, Shrime MG, et al. Health gains and finan-
cial risk protection afforded by public financing of selected interventions 
in Ethiopia: an extended cost-effectiveness analysis. Lancet Global Health. 
2015;3(5):e288–96.
 58. Nuti S, Vainieri M, Vola F. Priorities and targets: supporting target-setting 
in healthcare. Public Money Manag. 2017;37(4):277–84.
 59. Lim MK, Bae EY, Choi SE, Lee EK, Lee TJ. Eliciting public preference for 
health-care resource allocation in South Korea. Value Health. 2012;15(1 
Suppl):S91–4.
 60. Kapiriri L, Norheim OF. Criteria for priority-setting in health care in 
Uganda: exploration of stakeholders’ values. Bull World Health Org. 
2004;82(3):172–9.
 61. Shah KK. Severity of illness and priority setting in healthcare: a review of 
the literature. Health Policy. 2009;93(2–3):77–84.
